Your browser doesn't support javascript.
loading
Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta-analysis of 18 cohort studies.
Zhou, Ben-Gang; Jiang, Xin; She, Qiang; Ding, Yan-Bing.
Afiliación
  • Zhou BG; Dalian Medical University, Dalian, Liaoning Province, China.
  • Jiang X; Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China.
  • She Q; Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China.
  • Ding YB; Department of Gastroenterology, Affiliated Hospital of Yangzhou University, Yangzhou University, Yangzhou, Jiangsu Province, China.
Eur J Clin Invest ; : e14276, 2024 Jun 28.
Article en En | MEDLINE | ID: mdl-38943276
ABSTRACT

BACKGROUND:

Numerous recent studies have explored the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and the risk of various extrahepatic cancers. However, the conclusions were inconclusive. The aim of this study was to clarify this relationship by conducting a robust meta-analysis.

METHODS:

Systematic searches were conducted on PubMed, Embase and Web of Science databases to identify relevant cohort studies published prior to February 2024. Hazard ratios (HRs) and their corresponding 95% confidence intervals (95% CIs) were combined using a random-effects model in this meta-analysis.

RESULTS:

Eighteen cohort studies (approximately 16.7 million participants) were finally included in this meta-analysis. MASLD was linked to a higher risk of extrahepatic cancers, such as gastric (n = 10, HR = 1.47, 95% CI 1.07-2.01), colorectal (n = 13, HR = 1.33, 95% CI 1.16-1.53), pancreatic (n = 8, HR = 1.41, 95% CI 1.11-1.79), biliary tract (n = 5, HR = 1.27, 95% CI 1.18-1.37), thyroid (n = 6, HR = 1.46, 95% CI 1.02-2.09), urinary system (n = 10, HR = 1.45, 95% CI 1.25-1.69), breast (n = 11, HR = 1.17, 95% CI 1.08-1.26) and female genital organ cancers (n = 10, HR = 1.36, 95% CI 1.11-1.66). However, there was no statistically significant association between MASLD and the risk of head and neck (n = 6, HR = 1.03, 95% CI 99-1.07), oesophageal (n = 9, HR = 1.26, 95% CI 0.86-1.86), lung (n = 9, HR = 1.01, 95% CI 0.92-1.10), prostate (n = 9, HR = 1.06, 95% CI 0.94-1.19) or small intestine cancer (n = 2, HR = 1.75, 95% CI 1.00-3.06).

CONCLUSIONS:

This latest large-scale meta-analysis indicated that MASLD was associated with an increased risk of various extrahepatic cancers, such as gastric, colorectal, pancreatic, biliary duct, thyroid, urinary system, breast, skin and female genital cancers. Further research is needed to investigate the mechanisms underlying these associations.
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur J Clin Invest Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Eur J Clin Invest Año: 2024 Tipo del documento: Article País de afiliación: China